Skip Navigation


ToxSci Advance Access originally published online on March 15, 2008
Toxicological Sciences 2008 103(2):335-345; doi:10.1093/toxsci/kfn056
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
103/2/335    most recent
kfn056v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dykens, J. A.
Right arrow Articles by Will, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dykens, J. A.
Right arrow Articles by Will, Y.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

In Vitro Assessment of Mitochondrial Dysfunction and Cytotoxicity of Nefazodone, Trazodone, and Buspirone

James A. Dykens*, Joseph D. Jamieson{dagger}, Lisa D. Marroquin{dagger}, Sashi Nadanaciva{ddagger}, Jinghai J. Xu§, Margaret C. Dunn§, Arthur R. Smith§ and Yvonne Will,1

* Drug Safety Research and Development, Pfizer, Inc., Sandwich, UK CT139NJ {dagger} Drug Safety Research and Development, Pfizer, Inc., San Diego, California 92121 {ddagger} MitoSciences, Inc., Eugene, Oregon 97403 § Systems Biology, Pfizer Research Technology Center, Pfizer, Inc., Cambridge, Massachusetts 02139 Exploratory Safety Differentiation, Pfizer, Inc., Eastern Point, Groton, Connecticut 06340

1 To whom correspondence should be addressed. Fax: (860) 441-9637. E-mail: yvonne.will{at}pfizer.com.

Received January 24, 2008; accepted March 5, 2008


   Abstract

Mitochondrial toxicity is increasingly implicated in a host of drug-induced organ toxicities, including hepatotoxicity. Nefazodone was withdrawn from the U.S. market in 2004 due to hepatotoxicity. Accordingly, we evaluated nefazodone, another triazolopyridine trazodone, plus the azaspirodecanedione buspirone, for cytotoxicity and effects on mitochondrial function. In accord with its clinical disposition, nefazodone was the most toxic compound of the three, trazodone had relatively modest effects, whereas buspirone showed the least toxicity. Nefazodone profoundly inhibited mitochondrial respiration in isolated rat liver mitochondria and in intact HepG2 cells where this was accompanied by simultaneous acceleration of glycolysis. Using immunocaptured oxidative phosphorylation (OXPHOS) complexes, we identified Complex 1, and to a lesser amount Complex IV, as the targets of nefazodone toxicity. No inhibition was found for trazodone, and buspirone showed 3.4-fold less inhibition of OXPHOS Complex 1 than nefazodone. In human hepatocytes that express cytochrome P450, isoform 3A4, after 24 h exposure, nefazodone and trazodone collapsed mitochondrial membrane potential, and imposed oxidative stress, as detected via glutathione depletion, leading to cell death. Our results suggest that the mitochondrial impairment imposed by nefazodone is profound and likely contributes to its hepatotoxicity, especially in patients cotreated with other drugs with mitochondrial liabilities.

Key Words: nefazodone; trazodone; buspirone; hepatotoxicity; mitochondria; drug toxicity.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.